The Holladay Journal is the local newspaper covering news and events in the city of Holladay, Utah. The Holladay Journal provides one of the best advertising channels to the residents of the city of Holladay. Holladayjournal.com is the online lead...

Holladay Journal | Educating | Entertaining | Informing

Volatility Factor Academy Ltd

Volatility Factor Academy Ltd. Unveils Next-Generation AI-Driven Financial Infrastructure to Democratize Institutional Market Intelligence

NXP USA, Inc.

VSMC Celebrates the Grand Opening of Its First 300mm Fab in Singapore

Strengthens global semiconductor supply chain resilience; monthly capacity expected to reach 44,000 12-inch wafers by 2029

Shenghao

Shenghao Milly E03 Launches with Unpainted Resilient Body, Setting a New Standard for Family Mobility

Airwheel

Airwheel Smart Electric Cabin Suitcase Wins 2026 iLuxury Awards for SE3SX 20inch Rideable AI Wheel Boarding Carry-on Hand Travel Scooter Luxury Luggage

PECHOIN

PECHOIN Marks Its 10th Year at IFSCC, Showcasing Advances in Asian Skin Research

Aurra Markets

Aurra Markets Crowned 'Best Emerging Broker' at Forex Expo Dubai 2026

Nadula Hair

National Women’s Health and Fitness Day 2026: Nadula Encourages Women to Move Freely With Comfortable, Secure Hair Solutions

Yili Group

Yili Shares China's Whole-Value-Chain Dairy Symbiosis Model at FAO Global Conference

Xinhuanet

Ancient Wushu Meets AIGC: How Cangzhou Is Reimagining Its Cultural Story

RIMAN

RIMAN Expands Global Footprint to 22 Markets with Launches Across Europe and Latin America

Akeso, Inc.

Akeso Announces First Patient Enrolled in Global Phase III Trial of Cadonilimab Versus Nivolumab in First-Line Gastric Cancer

MIMS Accelerates Product Innovation and International Growth

Launch of new products, market expansion and AI-enabled capabilities mark the next stage of growth for a global healthcare technology company anchored by six decades of trusted medical data and expertise.

SINGAPORE –  Media OutReach Newswire – 28 September 2026 – MIMS Group, an Asia-Pacific provider of medicines information, clinical decision support, medical communications and marketing services, is accelerating product innovation and international growth as it transforms its long-standing healthcare data, content and market expertise into new technology platforms, customer applications and services. 
  Following the appointment of  Sohil Goswami as Group CEO in January 2026, MIMS has reshaped its businesses and leadership structure to support its next phase of growth. 
  The company is now ready to harness its data, technology and healthcare relationships to create scalable products and new business models across markets. 
  Clinical Decision Support expands across products and markets 
  MIMS recently launched  MIMS Pulse, its next-generation Clinical Decision Support platform that combines MIMS' medicines data and clinical knowledge with modern technology, flexible deployment and integration capabilities to support safer and more efficient clinical workflows. 
  Alongside MIMS Pulse, the company is scaling  eMIMS Plus, a platform that brings MIMS' trusted medicines information into a modern digital experience designed to achieve quality use of medicine. Conceived and first launched in Australia under Goswami's guidance in his previous role leading the CDS Business, eMIMS Plus is now available in India and Malaysia with plans to expand across Southeast Asia, introduce new clinical modules, as well as extend into new healthcare categories through  Drugs4Dent. 
  MIMS is developing its  global CDS offering, building on MIMS Pulse and eMIMS Plus to take its clinical data and technology capabilities into new markets and customer environments. 
  Medical Marketing business transforms for global growth 
  MIMS' Medical Communications business is expanding internationally, with commercial capabilities in the  US and UK creating opportunities with new client segments and global life sciences organisations. The business continues to develop digital events, AI-enabled content capabilities and new customer engagement models. 
  MIMS is exploring  more connected, intelligence-led services – helping healthcare and life sciences organisations better understand their markets, engage healthcare professionals and make more informed decisions. 
  This work represents an important step beyond MIMS' traditional information and communications models, applying its content data and market reach to new technology-enabled services. 
  Goswami said: 
  "For decades, healthcare professionals have trusted MIMS' medicines information and expertise. Today, we are transforming that foundation into the next generation of digital products, platforms and services. 
  We have been reshaping the business – bringing our capabilities together, strengthening our technology and building new ways to serve customers across markets. 
  Our opportunity is to turn trusted medical data, deep healthcare relationships and market knowledge into the next generation of products, platforms and services to build a MIMS that can compete and grow globally while staying relevant to the markets we serve." 
  The developments form part of a broader evolution across MIMS as the company builds on its established strengths while extending its products, capabilities and reach into new areas of healthcare. 
 Hashtag: #MIMS #MIMSPulse #eMIMSPlus #clinicaldecisionsupport #medicalmarketing #AIinhealth #digitalhealth #healthcareinnovation #healthtech #HCP 
The issuer is solely responsible for the content of this announcement.

About MIMS: Empowering Healthcare Communities to Improve Patient Outcomes
MIMS is Asia's largest multi-channel provider of drug information, medical communications, events management, marketing, and recruitment services. Established in 1963, our work empowers healthcare professionals to improve patient outcomes by facilitating knowledge exchange and better decision-making. Today, MIMS is present in 17 markets globally with over two million healthcare professional subscribers to our drug & resource portal, digital and print publications. 
  Combining healthcare communications expertise with our established networks and presence in the Asian healthcare community, we enable clients to engage their stakeholders in meaningful dialogue through a range of medical and marketing communications services. 
  We facilitate long-term placement of nurses, pharmacists and doctors across the globe to match the demands of healthcare institutions looking for high-calibre practitioners. 
  MIMS has offices in the following global markets: 
 Singapore (headquarters), Australia, China, Germany, Hong Kong SAR, Indonesia, India, Ireland, Japan, Korea, Malaysia, New Zealand, Philippines, Taiwan, Thailand, UAE, Vietnam 
  Learn more at  https://corporate.mims.com/ or follow  https://www.linkedin.com/company/mims-pte-ltd/

The Rosen Law Firm PA

CAR FINAL DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Avis Budget Group, Inc. Investors to Secure Counsel Before Important September 29 Deadline in Securities Class Action Against Pentwater Capital Management LP - CAR

AlphaPepe

Crypto News Today: AlphaPepe Presale Stage 20 Sold Out While Ethereum Price Prediction Targets $12,000

Inc. Names Fuel Logic to Its 2026 List of the Fastest-Growing Private Companies in the Southwest

Midlothian, TX September 27, 2026 --(PR.com)-- Companies on the Inc. Regionals: Southwest list had a median growth rate of 79 percent.
https://www.fuellogic.net/fuel-delivery-services/.
Contact Information:
Contact via Email
Read the full story here: https://www.pr.com/press-release/980061

Press Release Distributed by PR.com

Americare Supplements Launches Land & Sea Ancestral Superfood Stack

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages AppLovin Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – APP

HDB IMPORTANT DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages HDFC Bank Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action - HDB

SEEKOUT

SEEKOUT Moves Beyond Japan into North America and Europe, Accelerating Global Push in Premium Pet Market

HUTCHMED (China) Limited

HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors